- Home
- SIGA vs PRLD Comparison
SIGA vs PRLD Comparison
Compare SIGA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIGA | PRLD |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.0M | 325.7M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SIGA | PRLD |
|---|---|---|
| Price | $4.69 | $3.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | ★ 497.5K | 412.7K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 13.24% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | $224.81 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $4.10 | $0.75 |
| 52 Week High | $9.62 | $5.54 |
Technical Indicators
Market Signals| Indicator | SIGA | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 40.52 |
| Support Level | $4.29 | $1.14 |
| Resistance Level | $4.86 | $4.10 |
| Average True Range (ATR) | 0.19 | 0.37 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 71.52 | 11.59 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.